Celldex Therapeutics Inc.

29.35+3.21+12.28%Vol 2.20M1Y Perf -18.29%
Jun 24th, 2022 16:00 DELAYED
BID22.52 ASK29.90
Open26.56 Previous Close26.14
Pre-Market- After-Market29.35
 - -  - -%
Target Price
64.50 
Analyst Rating
Strong Buy 1.00
Potential %
119.76 
Finscreener Ranking
★★★★     54.41
Insiders Trans % 3/6/12 mo.
-/-/-88 
Value Ranking
★★★★+     58.80
Insiders Value % 3/6/12 mo.
-/-/-98 
Growth Ranking
★★★+     55.37
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-98 
Income Ranking
 —    -
Price Range Ratio 52W %
25.44 
Earnings Rating
Sell
Market Cap1.37B 
Earnings Date
4th Aug 2022
Alpha0.04 Standard Deviation0.58
Beta2.72 

Today's Price Range

25.2629.73

52W Range

19.8557.20

5 Year PE Ratio Range

-7.10-0.8000

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
26.18%
1 Month
13.54%
3 Months
-14.51%
6 Months
-30.12%
1 Year
-18.29%
3 Years
1 064.68%
5 Years
-25.32%
10 Years
-60.15%

TickerPriceChg.Chg.%
CLDX29.353.210012.28
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
26.10
26.80
0.00
0.01
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-1 854.70
-1 779.70
-2 158.30
-
RevenueValueIndustryS&P 500US Markets
4.14M
0.09
-4.54
-13.62
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.46-0.49-6.52
Q04 2021-0.42-0.43-2.38
Q03 2021-0.35-0.39-11.43
Q02 2021-0.40-0.3415.00
Q01 2021-0.32-0.42-31.25
Q04 2020-0.37-0.2629.73
Q03 2020-0.34-0.36-5.88
Q02 2020-0.77-0.5725.97
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.43-7.50Negative
9/2022 QR-0.49-4.26Negative
12/2022 FY-2.01-9.24Negative
12/2023 FY-2.34-5.41Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.43
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume2.20M
Shares Outstanding46.75K
Shares Float39.65M
Trades Count24.48K
Dollar Volume63.39M
Avg. Volume762.25K
Avg. Weekly Volume914.27K
Avg. Monthly Volume774.21K
Avg. Quarterly Volume598.25K

Celldex Therapeutics Inc. (NASDAQ: CLDX) stock closed at 29.35 per share at the end of the most recent trading day (a 12.28% change compared to the prior day closing price) with a volume of 2.20M shares and market capitalization of 1.37B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 130 people. Celldex Therapeutics Inc. CEO is Anthony S. Marucci.

The one-year performance of Celldex Therapeutics Inc. stock is -18.29%, while year-to-date (YTD) performance is -24.04%. CLDX stock has a five-year performance of -25.32%. Its 52-week range is between 19.85 and 57.2, which gives CLDX stock a 52-week price range ratio of 25.44%

Celldex Therapeutics Inc. currently has a PE ratio of -12.70, a price-to-book (PB) ratio of 2.54, a price-to-sale (PS) ratio of 231.46, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -24.42%, a ROC of -25.76% and a ROE of -26.49%. The company’s profit margin is -%, its EBITDA margin is -1 779.70%, and its revenue ttm is $4.14 Million , which makes it $0.09 revenue per share.

Of the last four earnings reports from Celldex Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Celldex Therapeutics Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Celldex Therapeutics Inc. is Strong Buy (1), with a target price of $64.5, which is +119.76% compared to the current price. The earnings rating for Celldex Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Celldex Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Celldex Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 28.41, ATR14 : 2.15, CCI20 : 187.63, Chaikin Money Flow : 0.30, MACD : -0.62, Money Flow Index : 76.45, ROC : 19.36, RSI : 62.81, STOCH (14,3) : 96.15, STOCH RSI : 1.00, UO : 71.22, Williams %R : -3.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Celldex Therapeutics Inc. in the last 12-months were: Anthony S. Marucci (Option Excercise at a value of $148 554), Diane C. Young (Option Excercise at a value of $47 748), Diane C. Young (Sold 4 600 shares of value $197 529 ), Elizabeth Crowley (Option Excercise at a value of $59 849), Elizabeth Crowley (Sold 8 317 shares of value $346 874 ), Freddy A. Jimenez (Buy at a value of $19 900), Margo Heath-Chiozzi (Option Excercise at a value of $93 501), Margo Heath-Chiozzi (Sold 1 200 shares of value $49 026 ), Sam Martin (Option Excercise at a value of $203 145), Sam Martin (Sold 21 738 shares of value $936 778 ), Sarah Cavanaugh (Option Excercise at a value of $121 333), Sarah Cavanaugh (Sold 14 646 shares of value $609 724 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Celldex Therapeutics Inc.

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.

CEO: Anthony S. Marucci

Telephone: +1 908 200-7500

Address: 53 Frontage Road, Hampton 08827, NJ, US

Number of employees: 130

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

66%34%

Bearish Bullish

56%44%

News

Stocktwits